APPLIED MICRO BEGINS CONCEPT SALESApplied Microbiology Inc. of New York said Wednesday thatsales of its first commercial product have begun in the UnitedStates. Consept, developed with strategic partner BabsonBrothers of Naperville, Ill., uses Applied's Ambicin-N anti-microbial peptide as an external dip to prevent bovinemastitis. Consept will be marketed by Babson. North Americansales of teat dips are about $100 million annually, accordingto the company (NASDAQ:APLY).

Applied also said it has signed a license and supply agreementfor a bovine mastitis preventative with Compagnie FrancaiseProduits Industrielles. CFPI plans to begin European sales in1992.


CytRx Corp., a Norcross, Ga., company developing therapeuticsincorporating copolymers, said Wednesday it has received its10th patent on its RheothRx product. The patent, No. 5,030,448,is for use of RheothRx in delivering drugs to damaged tissue.Because RheothRx enhances blood flow, the company(NASDAQ:CYTR) said the drug may improve delivery of otherdrugs. Burroughs Wellcome Co. has licensed rights to RheothRx,which is in clinical trials.


HemaCare Corp. said Tuesday it has received a Food and DrugAdministration establishment license and various bloodproduct licenses. The licenses enable the Sherman Oaks, Calif.,company (NASDAQ:HEMA) to sell certain blood products innational and international markets for the first time. In 1990,HemaCare had California blood product sales of $3.4 million.

(c) 1997 American Health Consultants. All rights reserved.